The Leukemia & Lymphoma Society’s Therapy Acceleration Program is a venture capital firm. Among the 6 companies in the known portfolio are Auron Therapeutics, Solu Therapeutics, Vittoria Biotherapeutics, Enterome, ImCheck Therapeutics and Rgenta Therapeutics.
Is The Leukemia & Lymphoma Society’s Therapy Acceleration Program a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
- Focus
- BiotechDrug DiscoveryGenomicsImmunotherapyOncologyPharmaVenture Philanthropy
The Leukemia & Lymphoma Society’s Therapy Acceleration Program portfolio companies (6)
- Auron Therapeutics
- Solu Therapeutics
- Vittoria Biotherapeutics
- Enterome
- ImCheck Therapeutics
- Rgenta Therapeutics
Co-investors
Funds that share portfolio companies with The Leukemia & Lymphoma Society’s Therapy Acceleration Program.
Similar funds
Showing 20 of 100
About The Leukemia & Lymphoma Society’s Therapy Acceleration Program
The firm's listing covers sector Healthcare, and focus areas Biotech, Drug Discovery, Genomics and Immunotherapy; known deals cluster at Series A and Series B.
The Leukemia & Lymphoma Society’s Therapy Acceleration Program shares portfolio companies with 20 other investment firms, among them ORI Capital, DCVC Bio and Alexandria Real Estate Equities.
Frequently asked questions
What is The Leukemia & Lymphoma Society’s Therapy Acceleration Program?
The Leukemia & Lymphoma Society’s Therapy Acceleration Program is a venture capital firm with a known portfolio of 6 companies. The portfolio comes from public investment records rather than from the firm, so deals that never surfaced publicly are not in it.
What does The Leukemia & Lymphoma Society’s Therapy Acceleration Program invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Drug Discovery, Genomics and Immunotherapy. Those tags come from the portfolio attached to the firm, so they describe what has been backed rather than a stated mandate for what comes next.
What stage does The Leukemia & Lymphoma Society’s Therapy Acceleration Program invest at?
The known deals of The Leukemia & Lymphoma Society’s Therapy Acceleration Program include Series A and Series B rounds. Check that against your own round before reaching out: stage mismatch is the most common reason a well matched sector still goes nowhere.
How do I contact The Leukemia & Lymphoma Society’s Therapy Acceleration Program?
Any email address on file for the firm is masked on this page and readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal